Close menu




September 14th, 2022 | 11:21 CEST

TUI, Almonty Industries, Bayer - Rebound after the sell-off?

  • Mining
  • Tungsten
  • travel
Photo credits: pixabay.com

Since September 8, the DAX has gained over 700 points despite inflation, a halt in Russian gas supplies and fears of recession. Inflation was 7.9% in August. The ECB's interest rate hike seems to have reassured many investors. The question remains whether the indices will again move to new highs. The S&P has broken its downward trend channel on a daily basis. No uptrend has been formed yet, but as long as the last lows are not broken again, it will continue to go up according to the chart technique. We therefore take a look at three companies that were recently sold off strongly and see whether there could be a sustainable rebound.

time to read: 4 minutes | Author: Armin Schulz
ISIN: TUI AG NA O.N. | DE000TUAG000 , ALMONTY INDUSTRIES INC. | CA0203981034 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
    "[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

    Full interview

     

    TUI - All bad news priced in

    With the outbreak of the Corona pandemic, TUI's business model came to a virtual standstill. Ongoing new virus variants and lockdowns brought the group deep into the red, and ultimately the German government rescued the ailing group. With Omicron, the endemic situation seemed to be within reach. Germans are regarded as the world's travel champions, and after two years of restrictions, they should be thirsting for vacations away from home. Good conditions for the group, but then came the Ukraine conflict. Energy prices went through the roof, and thus inflation also rose significantly. When the cost of living increases significantly, among other things, people save on their vacations.

    While the industry was still dreaming of record bookings at the beginning of the year, it was recently brought back down to earth. According to the Tats-Reisebüro-Spiegel, this year will not yet see a return to pre-Corona levels. Nevertheless, the latest quarterly figures give cause for hope. Sales increased by over 582% to around EUR 4.4 billion. EBIT increased significantly from EUR -630.5 million in 2021 to EUR -42.5 million. On a positive note, the statements by Health Minister Lauterbach, who recently ruled out lockdowns this fall and winter, can be viewed positively.

    After pretty much everything that can go wrong has gone wrong in recent years, a large part of this has probably already been priced into the share price. Much will depend on how well TUI's summer business went. However, the figures are not expected until December. The Group can no longer really surprise on the downside. After the last figures, management stuck to its forecasts and expects adjusted EBIT for the fiscal year to be significantly positive. The share recently formed a double bottom at around EUR 1.42, which can be seen as a bullish sign. Currently, the share price stands at EUR 1.66.

    Almonty Industries - Development of the mine is progressing

    Almonty Industries is in the process of building the largest tungsten mine outside of China. The metal is one of the critical raw materials on which China has a near monopoly. After renewed tensions between the US and China, a large independent producer would be essential to become less dependent on the two major tungsten producers, China and Russia. The Sandong mine in South Korea can provide between 7-10% of the world's tungsten supply and will do so for decades. The lifespan is stated to be at least 90 years. The financing is secured by KfW, and the first two tranches have already been disbursed.

    In addition to tungsten, the property also offers molybdenum deposits. On July 18, the Company released the first inferred mineral resource estimate of 21.48 tonnes at a molybdenum grade of 0.26%. There are greater synergies here as the project can be operated concurrently with the tungsten mine. This significantly reduces development costs and provides further upside potential for the Sangdong project. In addition to the property in South Korea, the Company has an existing producing tungsten mine called Panasqueira in Portugal. The experience gained from this mine will benefit the Company in developing the Sangdong mine.

    Despite the overall positive developments, the share recently came under significant pressure. From CAD 0.95 in mid-August, it went down to CAD 0.65 on September 12. The reasons are currently not discernible. The tungsten price has climbed by USD 100 in the last year to over 350 per metric ton. The Company already has a 15-year offtake agreement with Plansee in its pocket, which provides planning security. At the same time, it has strong anchor shareholders in CEO Lewis Black, Plansee and Deutsche Rohstoff. Perhaps the 4th International Investment Forum on September 27 can provide clarification here, as CEO Lewis Black will present the Company and answer any questions from shareholders.

    Bayer - Prostate cancer drug promises high sales

    After a rally at the beginning of March, Bayer's share price recently returned to square one. The main reason for this is energy prices, which are hitting the Chemicals division in particular. Production declines of up to 10% were recently reported in this sector. In addition to the current energy issue, the glyphosate lawsuits are still causing uncertainty among investors. After the cases suffered a setback in mid-July, some victories were recently achieved. So things are looking up here. While the Chemicals division is struggling with difficulties, the Pharmaceuticals division is doing well.

    The Group recently presented positive study data on the new prostate cancer drug Nubeqa at the ESMO Cancer Congress. On the one hand, the active ingredient extends life expectancy; on the other hand, it delays the onset of symptoms. Initial approval has been granted in the USA, with the EU, China and Japan to follow shortly. Applications have already been filed. The Group expects the drug to generate sales of up to EUR 3 billion, which would give Bayer its next blockbuster. On September 13, dpa reported that the head of Bayer's Supervisory Board was looking for a replacement for current CEO Werner Baumann.

    The contract was not to be extended anyway, but perhaps something will change at the top of the group sooner. Since August, there have been 9 buy recommendations for the stock, with price targets ranging between EUR 70.00 and 98.00. The analysts from Jeffries were the most cautious, while Bernstein Research saw the most potential. Currently, one pays EUR 55.09 for a share certificate. Investors should note November 8 because that is when the Group presents its Q3 results.


    In Germany, there is a certain consumer restraint due to inflation and fear of recession. For TUI, this could become a problem. Here, one should still wait and see. Almonty Industries, on the other hand, is on its way to becoming the largest tungsten producer outside China. The construction of the mine has been financed, and production is foreseeable. Bayer's pharmaceuticals division is doing well, while the chemicals division is suffering from the energy problem. Here, the following quarterly figures will be interesting.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by André Will-Laudien on March 28th, 2024 | 09:00 CET

    Attention: Uranium despite the energy transition! Does this fit together? Plug Power, Nel ASA, Kraken Energy and Renk Group in focus

    • Mining
    • Uranium
    • Energy
    • renewableenergies
    • nuclear

    It feels like a paradox. The EU aims to be largely climate-neutral by 2050. The main focus is on mobility, heat and energy generation. As a core country of the EU, Germany is taking the political lead in the necessary measures. While France, Poland, Finland and the Czech Republic are actively expanding nuclear energy, this form of energy is virtually taboo in many other countries. Germany has been able to increase its renewable energy sources to over 50% with billions in subsidies at the expense of the taxpayer and the price of energy. Yet, Berlin still has to buy cheap electricity from abroad and also use coal and gas to stabilize the grid. It all sounds kind of crazy, but it gets really interesting when the wind isn't blowing and the sun is only to be found behind the clouds. Which shares should be considered in this mixed situation?

    Read

    Commented by Juliane Zielonka on March 28th, 2024 | 08:50 CET

    Rheinmetall, Almonty Industries, Bayer AG - Arming up for defense with these stocks

    • Mining
    • Tungsten
    • armaments
    • Pharma

    The European Union is providing the defense group Rheinmetall with a total of EUR 130 million for ammunition production. The German company is one of six EU projects that are being funded in a special program to stockpile enough artillery pieces and secure supply chains. Here, Almonty Industries comes into play. Almonty specializes in the exploration, extraction and production of tungsten in two European countries, including Spain and Portugal. Tungsten is used in particular for ammunition. Almonty Industries also operates five mining projects, one of which is the largest tungsten project in South Korea. The increasing demand for the critical metal will soon cause the price of tungsten to skyrocket, as defense is becoming increasingly important for the countries and continents involved in the face of geopolitical tensions worldwide. Defense is also a topic at Bayer. The cancer drug Nubeqa supports the body's immune system in the fight against prostate cancer. Following the recent pipeline flop with Asundexian, the drug has great blockbuster potential and could bring billions of euros into the Company's coffers. Read more about why this is so important for Bayer at the moment.

    Read

    Commented by Armin Schulz on March 28th, 2024 | 08:45 CET

    TUI, dynaCERT, Evotec - The profit is in buying

    • Hydrogen
    • greenhydrogen
    • travel
    • Biotechnology

    In the world of the financial markets, the timeless maxim applies: "The profit is in buying". This tried and tested stock market adage, which may seem trivial at first glance, is actually the key to financial success. Indeed, the price at which an investment is purchased often determines its subsequent triumph or failure long before the sale is even considered. Despite advances in technology and the complexity of markets, the basic lesson remains - buying wisely and at a well-considered price lays the foundation for profits. We have picked out three interesting candidates.

    Read